MUC1 and neoplasm: Several clinical trials are also currently underway to evaluate the anti-tumor efficacy of CAR T-cells producing antibodies against CTLA-4 and PD-1 in MUC1+, EGFR+, and mesothelin+ solid tumors (NCT03179007, NCT03182816, and NCT03182803).